RecruitingCirrhosisSplenectomyPortal Vein Thrombosis
Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD
Eligible age
18+ yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to determine whether Apixaban is effective and safe in the treatment of portal vein thrombosis Occurring more than one year after laparoscopic splenectomy and azygoportal disconnection.
Sponsor: Northern Jiangsu People's Hospital
You may qualify if…
- ✓ 1. A clinical, radiological, or histologic diagnosis of cirrhosis of any etiology.
- ✓ 2. Portal hypertension bleeding .
- ✓ 3. Splenomegaly with secondary hypersplenism.
- ✓ 4. No evidence of portal vein thrombosis by ultrasound evaluation and angio-CT prior to surgery.
- ✓ 5. Underwent laparoscopic splenectomy at our center.
- ✓ 6. Orally received 2.5 mg of apixaban (CTTQ, Nanjing, China) twice daily or a 100 mg aspirin tablet (Bayer, Leverkusen, Germany) once daily for 6 months from POD 3.
- ✓ 7. subcutaneous injections of low molecular weight heparin sodium (CSBio, Hebei, China) were administered for 5 days from POD 3
- ✓ 8. Oral dipyridamole (Henan Furen, Henan, China) at a dosage of 25 mg, administered three times daily for 3 months from POD 3.
You may not qualify if…
- ✕ 1. Hepatocellular carcinoma or any other malignancy.
- ✕ 2. Hypercoagulable state other than the liver disease related.
- ✕ 3. DRUGS- oral contraceptives, anticoagulation or anti-platelet drugs.
- ✕ 4. Child - Pugh C
- ✕ 5. Recent peptic ulcer disease
- ✕ 6. History of Hemorrhagic stroke
- ✕ 7. Pregnancy.
- ✕ 8. Uncontrolled Hypertension
Source: ClinicalTrials.gov · NCT07461532 · last updated 2026-03-31